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Abstract
Hydrolases containing two metal ions connected by a bridging ligand catalyze reactions important in
carcinogensis, tissue repair, post-translational modification, control and regulation of biochemical pathways,
and protein degradation. The aminopeptidase from Aeromonas proteolytica serves as a paradigm for the study
of such bridged bimetallic proteases since its three-dimensional structure is known to very high resolution and
its catalytic reaction is amenable to spectroscopic examination. Herein, we report the X-ray crystal structure at
1.9 Å resolution of AAP complexed with 1-butaneboronic acid (BuBA). This structure suggests that this complex
represents a snapshot of the proteolytic reaction in an arrested form between the Michaelis complex and the
transition state. Comparison of the structure with spectroscopic and other data allows us to conclude that the
apparently structurally symmetrical dizinc site is actually asymmetric electrostatically.
This work was supported by the National Science Foundation (CHE-9816487 to RCH), by the National Institutes
of Health (GM26788 to GAP and DR), and, in part, by the Macromolecular Structure and Mechanisms Training
Grant from the NIH (CCD).

Hydrolases that contain two metal ions connected by a bridging ligand catalyze such diverse reactions as the
degradation of DNA, RNA, phospholipids, and polypeptides (1−4). They are, therefore, key players in
carcinogenesis, tissue repair, protein maturation, hormone-level regulation, cell-cycle control, and protein
degradation processes. In addition, binuclear metallohydrolases are involved in the degradation of agricultural
neurotoxins, urea, antibiotics, and several phosphorus(V) materials used in chemical weaponry (5−7). These
enzymes use different metal ion Lewis acidities in discrete binuclear sites to (1) bind and position substrate, (2)
bind and activate a water molecule to yield an active site hydroxide nucleophile, and/or (3) stabilize the
transition state of the hydrolytic reaction. Despite their ubiquity and the considerable structural information
available, little is known about how bridged bimetallic centers function during catalytic turnover.
The binuclear metallo-aminopeptidases catalyze the hydrolysis of N-terminal amino acid residues from proteins
and polypeptides and are typically grouped into two distinct subclasses: those that are capable of removing
nearly any amino acid from the N-terminus of a polypeptide chain and those that selectively remove methionine
(8−10). All of these enzymes are widely distributed in bacteria, yeast, plant, and animal tissues (10). Abnormal
aminopeptidase activity has been associated with many health conditions and pathologies, including aging,
cataracts, inflammation, cystic fibrosis, cancer, and leukemia; thus, their biological and medicinal significance is
immense (8−10). For example, the naturally occurring peptide-analogue inhibitor, bestatin, was recently shown
to significantly decrease HIV infection in males by inhibiting leucine aminopeptidase activity (11). Moreover, a
recent study has shown that several naturally occurring aminopeptidase inhibitors (i.e., bestatin, leuhistin, and
actinonin) inhibit matrix degradation and invasion of extracellular matrixes by fibrosarcoma cells (12). Thus, the
inhibition of aminopeptidase activity at malignant tumors is critically important in preventing the growth and
proliferation of cancer. This fact is underscored by the recent observation that the eukaryotic binuclear

metallohydrolase methionine aminopeptidase II is the target for the antitumor drugs ovalicin and fumagillin (13,
14).
The dizinc aminopeptidase from Aeromonas proteolytica (AAP) is a small, monomeric enzyme (32 000 Da),
thermostable for several hours at 70 °C, that has been previously crystallographically characterized (15, 16). AAP
possesses a (μ-aqua)(μ-carboxylato)dizinc(II) core with a terminal carboxylate and histidine residue at each
metal (Figure 1). Both Zn(II) ions in AAP have a distorted tetrahedral coordination geometry with a Zn−Zn
distance of 3.5 Å. The X-ray crystal structure of AAP complexed to the transition state analogue inhibitor diodophenylalanine hydroxamate shows that a single oxygen atom of the hydroxamate inhibitor bridges between
the two active-site Zn(II) ions with the concomitant loss of the bridging water molecule (16). This structure is
similar to the transition state analogue inhibited structures of bovine lens aminopeptidase (blLAP) complexed
with l-leucinal and l-leucine phosphonic acid (LPA) (17, 18) and AAP bound by LPA (19). These structures of
transition state analogue complexes have been interpreted as representing one stage of the reaction
mechanism.

Figure 1 Stereoimage of the native AAP active site calculated from coordinates 1AMP, (15). The zinc ions of the
binuclear center have symmetric coordination spheres in that each has a terminal carboxylate and histidine
residue in addition to the bridging aspartate and water molecule. Glu151, also shown, is not a metal ligand but is
thought to participate in the hydrolytic reaction.
Herein, we present the X-ray crystal structure, at 1.9 Å resolution, of AAP coordinated by the competitive
inhibitor 1-butaneboronic acid (BuBA). Comparison of this structure with spectroscopic and X-ray
crystallographic data from the binding of both substrate and transition state analogues of peptide hydrolysis
reveals that the BuBA complex represents a snapshot of the proteolytic reaction in an arrested form between
the Michaelis complex and the transition state. Combination of these data with previously reported
spectroscopic and X-ray crystallographic data have allowed a detailed mechanism of action to be proposed for
the metal-mediated peptide hydrolysis reaction catalyzed by AAP.

Materials and Methods
Purification of AAP.
All chemicals used in this study were purchased commercially and of the highest quality available. The AAP was
purified from a stock culture kindly provided by Professor Céline Schalk. Cultures were grown according to the
previously published procedure (20) with minor modifications to the growth media (21). Purified enzyme was
stored at −80 °C until needed.

Spectrophotometric Assay of AAP.
AAP activity was measured by the method of Prescott and Wilkes (22) as modified by Baker et al. (23). In this
assay, the hydrolysis of 0.5 mM l-leucine-p-nitroanilide (10 mM Tricine, pH 8.0, containing 0.1 mM ZnSO4) was
measured spectrophotometrically at 25 °C by monitoring the formation of p-nitroaniline. The extent of
hydrolysis was calculated by monitoring the increase in absorbance at 405 nm (Δε405 value of p-nitroaniline of
10 800 M-1 cm-1) (23). One unit was defined as the amount of enzyme that releases 1 μmol of p-nitroaniline at 25

°C in 60 s. The specific activity of purified AAP was typically found to be 120 units/mg of enzyme. This value is
identical to that reported by Prescott and Wilkes (20). All spectrophotometric assays were performed on a
Shimadzu UV-3101PC spectrophotometer equipped with a constant temperature cell holder. Enzyme
concentrations were determined from the absorbance at 278 nm with the value ε278 = 41 800 M-1 cm-1 (24).

Crystallization, Data Collection, and Processing.
AAP was cocrystallized with BuBA using the crystallization conditions reported for the native enzyme (25),
following preincubation with a 4-fold molar excess of BuBA. The purified AAP (10 mg·mL-1) in 10 mM Tris at pH
8.0, 10 mM KSCN, 0.4 M NaCl, and 4-fold molar excess of BuBA was crystallized by vapor diffusion using 100 mM
Tris at pH 8.0, 100 mM KSCN, and 4.5 M NaCl as the precipitating solution. Crystals with dimensions 0.7 × 0.4 ×
0.4 mm3 were obtained in 2 days and were shown to be isomorphous with the native crystals.
Diffraction data were collected at 4 °C on an R-axis IIC Image plate area detector system mounted on a Rigaku
RU-200B rotating anode generator, operating at 45 kV and 130 mA. A 0.5 mm collimator was used, and the
crystal to detector distance was 100 mm. One crystal was used with one orientation, but the oscillation step size
was changed from 1 to 0.5 deg before completing the data collection. The data were processed using XDS97
(26). The data processing and refinement statistics are outlined in Table 1. The overall completeness of 84% was
lowered by the completeness of the outermost shell. In the outermost shell (2.1−1.9 Å), the completeness was
only 46.7%, whereas the completeness in the next resolution shell (2.3−2.1 Å) was 93%. The Rmerge in this
outermost shell was 37.8%, resulting in an overall Rmerge (on I) of 13.4%, including these data. Ultimately, the
decision to keep all of the data to 1.9 Å was based on the quality of the electron density maps where these data
were included.
Table 1: Data Collection and Refinement Statistics
Crystal Data
space group
unit cell parameters (Å)
a
b
c
Data Processing
no. of reflections, observed
no. of reflections, unique
cutoff (I/σ)
Rmergea (overall) (%)
completeness, overall (%)
highest resolution shell (Å)
completeness, outer shell (%)
Model Refinement
resolution range (Å)
cutoff (F/σF)
R-factorb (%)
no. of reflections
Rfree (%)
no. of reflections
no. of protein atoms
no. of zinc ions
no. of BuBA atoms

P6122
109.2
109.2
97.7
163 530
23 658
0
13.4
84.2
1.9−2.1
46.7
10−1.9
0
19.3
21 322
22.9
2336
2211
2
6

no. of water molecules
134
B-factor model
individual
rmsd from ideality
bond lengths (Å)
0.006
bond angles (deg)
1.16
improper angles (deg)
0.61
dihedral angles (deg)
25.8
residues in most favored positionsc (%)
87.2
a
b
c
Rmerge = ∑|Iobs − Iavg|/∑Iavg. R-factor = ∑|Fobs − Fcalc|/∑|Fobs|. As determined by the program PROCHECK.
Structure Solution and Refinement. Since the crystal of the BuBA-inhibited enzyme was isomorphous with that of
the native enzyme, the phases from the published native structure (1AMP, ref 15) were used as the starting
model (15). In this process, the zinc atoms and water molecules were omitted from the original coordinate file.
All refinement procedures were carried out using the software package X-PLOR (27), and the initial model was
subjected to a rigid body refinement using reflections in the 20−4.0 Å resolution range. Subsequent rounds of
positional refinement were carried out using higher resolution data incrementally to 1.9 Å resolution. The Rfactor and R-free (28) at this point were 0.27 and 0.31, respectively. Difference electron density maps with
coefficients 2Fobs − Fcalc and Fobs − Fcalc (29, 30) were then calculated; these showed clear electron density in the
active site for the missing zinc atoms as well as bound inhibitor and a water molecule in close proximity to the
bound inhibitor. The two zinc ions and several water molecules were added, and the model was subjected to
further rounds of positional refinement. To avoid any bias toward the form of the inhibitor during refinement of
the structure, the inhibitor was not yet built into the electron density. Only after several more rounds of
refinement and the addition of more water molecules were the coordinates for BuBA built into the electron
density. A model for BuBA was built using QUANTA (Molecular Simulations, Inc.) in an almost pyramidal
arrangement. This model of BuBA was fitted into the observed electron density in a form having only two
oxygen ligands. This electron density showed no sign of a third oxygen atom attached to the boron atom.
Because the density at the boron atom was clearly not planar, the parameter files for the inhibitor were edited
such that the constraints placed on all angles within the inhibitor were relaxed during refinement. Without
relaxing these constraints, the inhibitor was not able to fit the electron density accurately.
An attempt was made to build into the electron density a form of the inhibitor having three oxygen atoms
around the boron atom, despite the lack of visible electron density for the third oxygen. This was impossible,
however, because of the extremely close proximity of water-53. The distance between this water molecule and
the putative third oxygen atom was only 1.1 Å. This information combined with the lack of electron density for a
third oxygen caused us to build the inhibitor with only two oxygen atoms. To be sure that the distance between
the boron atom and water-53 was not due to deficiencies in the parameters used, the structure was also
subjected to a refinement protocol in which all van der Waals and electrostatic interaction terms between
water-53 and BuBA were turned off. The distance between water-53 and the boron atom remained unchanged
after such refinement.
The electron density for the inhibitor did not extend to the last carbon of BuBA, and this carbon was, therefore,
not built into the structure. Further rounds of positional refinement as well as overall and individual B-factor
refinement resulted in a final structure with an R-factor of 0.19 and an R-free of 0.23. At this resolution the
anticipated error in the coordinate positions is 0.1−0.2 Å. In addition to the 291 amino acid residues, the final
model contains 2 zinc ions, 134 water molecules, and 6 atoms of the inhibitor molecule. The terminal carbon of
BuBA was omitted due to lack of electron density. Simulated annealing omit maps, in which the active site
region was omitted, were calculated and confirmed the presence and the geometry of the bound inhibitor and
water-53.

Results and Discussion
Spectroscopic and crystallographic studies on aminopeptidases, to date, have focused on the native enzymes
and analogues of the tetrahedral transition state of peptide hydrolysis. These include studies on transition state
analogue complexes of both bovine lens leucine aminopeptidase (blLAP) and AAP, which have been interpreted
in terms of various catalytic steps (16−18, 31, 32). For AAP, kinetic, optical, and EPR data on the binding of lleucinephosphonic acid (LPA) to the dicobalt(II)-substituted ([CoCo(AAP)]) enzyme and the heterobimetallic
([CoZn(AAP)] and [ZnCo(AAP)]) enzymes suggested that a single oxygen atom bridge is not present in this
complex (19). Since LPA was shown to interact with both metal centers, LPA was proposed to bind to the
binuclear cluster of AAP as an η-1,2-μ-phosphonate with one of the ligands at the second divalent metal ion
provided by the N-terminal amine. The proposed structure for LPA binding is consistent with preliminary X-ray
crystallographic data for [ZnZn(AAP)] bound by LPA (De Paola, unpublished results). The X-ray crystal structure
of the transition state analogue inhibitor d-iodophenylalanine hydroxamate bound to AAP also indicated both
metal ions are involved in binding the inhibitor (16). Similarly, X-ray crystal structures of blLAP with the
transition state analogue inhibitors LPA and l-leucine bound to the binuclear Zn(II) cluster show that both
inhibitors provide a single oxygen atom bridge between the two Zn(II) ions (17, 18). These data suggest that in
the transition state of peptide hydrolysis, both metal ions are involved in coordinating the tetrahedral
intermediate.
A mechanism was proposed for blLAP in which both active site metal ions function as Lewis acids (18). In this
mechanism, a bridging hydroxide ion acts as the nucleophile by attacking the scissile carbonyl carbon of the
peptide substrate. However, for AAP, a mechanism like that of thermolysin or carboxypeptidase A was proposed
on the basis of an active-site carboxylate that forms a hydrogen bond to the bridging oxygen atom of the
inhibitor d-iodophenylalanine hydroxamate (16, 31, 32). These structures of transition state analogue complexes
have been interpreted as representing one stage of the reaction mechanism. Consequently, a number of aspects
of the hydrolytic chemistry catalyzed by the binuclear metal clusters of aminopeptidases have gone unexplored.
To examine the interactions of an AAP complex representing an earlier stage of the reaction, we have
crystallized AAP in the presence of the putative substrate analogue inhibitor 1-butaneboronic acid (BuBA). The
structure of the AAP−BuBA complex has been determined to 1.9 Å resolution (Figure 2).

Figure 2 Ribbon diagram of the X-ray crystal structure of AAP complexed with 1-butaneboronic acid (BuBA)
(top). The two zinc(II) ions are depicted as gray spheres. The bridging Asp117 is also shown. Stereoimage of the

AAP−BuBA complex active site (bottom). BuBA is bound asymmetrically with respect to the zinc ions. In this
view, water-53 is located behind BuBA.
Boronic acids have been reported to be competitive, slow-binding inhibitors of aminopeptidases. For instance,
α-aminoboronic acids are known to be biphasic slow-binding aminopeptidase inhibitors (33). The boronic acid
BuBA (Ki = 10 μM at pH 8.0) (34) binding to AAP has been previously studied by probing the [CoCo(AAP)],
[CoZn(AAP)], and [ZnCo(AAP)] enzyme−complexes by EPR spectroscopy (35, 36). The addition of BuBA to
[CoZn(AAP)] resulted in a distinct change in the EPR spectrum; however, addition of BuBA to [ZnCo(AAP)] left the
EPR spectrum completely unperturbed. These data are similar to those obtained from electronic absorption
spectroscopy (37) and indicate that BuBA binds only to the first metal binding site of AAP and does not interact
with the second site. Furthermore, the addition of 1 equiv of BuBA to [CoCo(AAP)] resulted in the immediate
loss of an integer spin (S = 3) EPR signal observed in the parallel mode, suggesting that upon BuBA binding the μaquo bridge between the Co(II) ions is lost and becomes terminal on the first metal-binding site (31, 38). The
newly generated terminal water/(OH-) then becomes a candidate for the nucleophile in the enzymatic reaction.
Comparison of these data with the spectroscopic and X-ray crystallographic results for transition-state-analogue
inhibitors suggests that BuBA mimics the substrate binding step rather than the transition state (36).
BuBA binding to AAP does not induce major conformational changes in the protein, and the structures of the
native AAP and AAP−BuBA complex agree well with an rms deviation of 0.17 Å for the 291 structurally
equivalent Cα atoms (Figure 2). The two Zn(II) atoms are 3.3 Å apart in the BuBA complex compared to 3.5 Å in
the native structure. This difference is not significant at this resolution. The amino acid residues ligated to the
dizinc(II) cluster are identical to those of the native structure with only minor perturbations to the bond lengths
(Figure 3, Table 2). The BuBA oxygen atoms are 2.5 and 2.7 Å from Zn1 and 3.0 and 4.4 Å from Zn2 suggesting
that BuBA binds only to Zn1 and not to Zn2, consistent with previous EPR studies (35).

Figure 3 Schematic of BuBA bound to AAP with distances (Å) shown for all ligands to the zinc ions and for water53.
Table 2: Selected Bond Lengths (Å) for the Zinc-ligand Distances in the AAP−BuBA Complex
zinc−ligand
Zn1−Zn2
Zn1−Asp117 O2
−Glu152 O1
−Glu152 O2

zinc−ligand distance (Å)
native
3.5
2.1
2.0
2.4

BuBA complex
3.3
2.2
2.2
2.6

−His256 N2
bridging H2O/OH−BuBA O1
−BuBA O2
Zn2−Asp117 O1
−Asp179 O1
−Asp179 O2
−His97 N2
bridging H2O/OH−BuBA O2
−BuBA O1
water-53−boron
−Zn1
−Zn2

2.3
2.3

2.0
2.1
2.3
2.3
2.3

2.3
2.5
2.7
2.1
2.2
2.5
2.2
3.0
4.4
2.4
4.3
4.8

An interesting finding in this study is that the boron atom of BuBA is clearly not trigonal planar (sp2) but is
trigonal pyramidal (sp3) (Figure 4). In the absence of enzyme, BuBA was reported to be >99% in the boronic acid
form (sp2 hybridized) at pH 8.0, with a reported pKa of 10.62 (34). Therefore, the loss of planarity about the
boron atom must be the result of binding to the binuclear active site of AAP. In addition, there is no electron
density near the two Zn(II) ions that would suggest a bridging water between them in the AAP−BuBA complex. A
new water molecule (water-53) that was not present in the native structure resides 2.4 Å from the boron atom
of BuBA. Although rather far from both Zn(II) ions (4.3 Å from Zn1 and 4.8 Å from Zn2), water-53 may in fact
represent the nucleophile in the catalytic reaction since it resides on the correct side of the boron atom to have
been delivered by Zn1. Moreover, it is well positioned for an in-line attack on the carbonyl carbon atom of the
peptide substrate if the N-terminal amino acid were bound analogously to BuBA with the carbonyl carbon in the
position of the boron atom. On the basis of these data, it is reasonable to propose that the sp2 hybridized form
of BuBA binds to the dinuclear active site of AAP via the coordination of O1 to Zn1. This initial binding step
would then be followed by attack of the active site Zn1-bound water/(OH-) to the electron deficient pz orbital of
the boron atom, making it sp3. These data are consistent with previous kinetic studies on BuBA binding to AAP,
which indicated that BuBA binds in a two-step process (34, 37) analogous to the binding of boronic acids to
serine proteases (38). Therefore, the AAP−BuBA complex could represent the proteolytic reaction in an arrested
form between the Michaelis complex and the transition state. This structure of a reaction intermediate is the
only one of its kind for a binuclear hydrolytic system.

Figure 4 Final difference electron density map with coefficients 2Fobs − Fcalc contoured at 1.2σ showing the two
zinc ions, BuBA, and water-53, proposed to be the active site nucleophile. For clarity, the electron density of the
protein ligands to the metal ions has been omitted from this figure.
The boron atom of BuBA bound to AAP appears to be in a tetrahedral form with a water molecule or a hydroxyl
ion nearby. Thus, the question arises: why is the AAP−BuBA complex not a reasonable mimic for a posttransition state structure? This question is based on the expectation that hydrolysis of the peptide bond occurs
by the formation of a tetrahedral intermediate and the additional expectation that the transition state leading
to this intermediate is similar in structure. Since one expects the distances between boron and oxygen to be
almost equal for the ionized boronate and since the distance between water-53 and the boron atom is long (2.4
Å), this is indicative of an early event surrounding the transition state. The fact that an arrested form of the
catalytic reaction is observed even though this is not a thermodynamically stable step along the catalytic
pathway is likely due entirely to the inhibitor, BuBA. First, when the boron atom of BuBA is sp2hybridized with a
trigonal planar geometry, the pz orbital is empty and the boron is deficient making the boron an excellent Lewis
acid. Moreover, upon binding of the O1 oxygen atom of BuBA to Zn1, the boron atom of BuBA will become more
electron deficient. This results in the boron atom of BuBA becoming even more susceptible to nucleophilic
attack by an active-site water/(OH-) molecule. Second, the n-butyl tail is a poor leaving group, and the
boron−carbon bond cannot be broken. Consequently, the hydrophobic interactions between the n-butyl group
and the hydrophobic pocket may be sufficiently inflexible so that the oxygen atom of BuBA, that is 3.0 Å from
Zn2, cannot move enough to bind to Zn2, forming a transition state type structure.
The binuclear center in the native enzyme is structurally symmetric (15), and AAP is ca. 80% active with only a
single metal ion bound (35, 39). These observations pose an important mechanistic question: what is the driving
force to break the Zn2−OH(H) bond, leaving the putative nucleophile (OH-) and the substrate on the same zinc
(Zn1) ion? Several active-site amino acid residues that do not act as Zn(II) ligands form hydrogen bonds within
the active site. One of these, Glu151, contains an oxygen atom that in the AAP−BuBA complex is 3.0 Å from the
coordinated Nε-nitrogen atom of His97, which is a ligand to Zn2. This distance is significantly shorter than the
3.4 Å distance found in the native structure and allows for a hydrogen bond between Glu151 and His97 that may
not have existed in the native structure, or only existed weakly or transiently. These data suggest that Glu151

may contribute to the regulation of the Lewis acidity of Zn2. A second hydrogen bonding interaction is observed
between Asp99 and His97 forming an Asp-His-Zn triad. An oxygen atom of Asp99 is 2.7 Å from the Nδ-nitrogen
of His97, suggesting a strong hydrogen bonding interaction. Strong hydrogen bonds between active site Asp
residues and histidine ligands in zinc metalloproteins have been shown previously to provide a histidinate-like
ligand (40), thus decreasing the Lewis acidity of Zn(II) ions. For Zn2, coordination of Asp179 and Asp117 results
in significant negative charge around the metal ion. Therefore, the hydrogen bond between His97 and Asp99
provides a histidinate-like ligand that allows Zn2 to retain charge neutrality. If this hydrogen bond is sufficiently
strong, which appears to be the case in the AAP−BuBA structure, this interaction may also decrease the Lewis
acidity of Zn2 sufficiently to assist in the loss of the bridging water/(OH-). The combination of these hydrogen
bonding interactions may, therefore, act to destroy the local symmetry of the binuclear cluster as well as
decrease the Lewis acidity of the Zn2 ion, allowing both the substrate and nucleophile to reside on the Zn1 site.
On the basis of previously reported kinetic, thermodynamic, spectroscopic, and X-ray crystallographic data a
detailed mechanism of action for AAP has recently been proposed (19, 35, 36). In this mechanism, the bridging
water/(OH-) becomes terminal upon substrate binding and remains associated with the Zn1. An active-site
carboxylate group, Glu151, has been implicated in the catalytic process from X-ray crystallographic data since
Glu151 forms a hydrogen bond with the bridging water/(OH-) molecule in the resting enzyme (15). The role of
Glu151 could be to assist in the deprotonation of the terminal water molecule to the nucleophilic hydroxo
moiety, a role similar to that proposed for Glu270 in carboxypeptidase A (41). Our structural data for the
AAP−BuBA complex are consistent with this mechanism. Recent studies by us on the structures of peptidederived inhibitors bound to AAP are also consistent with this picture, and the terminal amino group of these
peptide analogues is observed to coordinate to Zn2 (19, De Paola, unpublished results). N-Terminal amine
binding to Zn2 suggests that electron density donation by the second metal ion is important in stabilizing the
transition state. Similarly, amine binding to the second Mn(II) ion in arginase has been proposed to drive the loss
of the bridging water/(OH-) to form a terminal hydroxide that functions as the nucleophile in that hydrolytic
reaction (42). On the basis of these data, we propose that N-terminal amine binding, in conjunction with
hydrogen-bonding interactions between Glu151 and/or Asp99 with His97, could function to displace the
bridging water/(OH-) thus placing it on Zn1 along with the substrate. At this point, the metal-bound hydroxide
can attack the activated scissile carbonyl carbon of the peptide substrate, forming a gem-diolate intermediate
complex that is stabilized by coordination of both oxygen atoms to the dizinc(II) center. Glu151 can then provide
an additional proton to the penultimate amino nitrogen returning it to its ionized state. Finally, the dizinc(II)
cluster releases the cleaved products followed by the addition of a water molecule to bridge between the two
metal ions. This model predicts that both metal ions are required for full enzymatic activity by this mechansim,
but their individual roles differ markedly.
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